Your browser doesn't support javascript.
loading
Desloratadine via its anti-inflammatory and antioxidative properties ameliorates TNBS-induced experimental colitis in rats.
Bhat, Mohammad Aadil; Roy, Supriya; Dhaneshwar, Suneela; Kumar, Swatantra; Saxena, Shailendra K.
Afiliação
  • Bhat MA; Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India.
  • Roy S; Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India.
  • Dhaneshwar S; Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai, Maharashtra, India.
  • Kumar S; Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Uttar Pradesh, Lucknow, India.
  • Saxena SK; Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Uttar Pradesh, Lucknow, India.
Immunopharmacol Immunotoxicol ; 46(4): 436-449, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38816915
ABSTRACT

BACKGROUND:

Intestinal mucosal immune cells, notably mast cells, are pivotal in ulcerative colitis (UC) pathophysiology. Its activation elevates tissue concentrations of histamine. Inhibiting colonic histamine release could be an effective therapeutic strategy for treating UC. Experimental model like 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats mimic human IBD, aiding treatment investigations. Drug repurposing is a promising strategy to explore new indications for established drugs. Desloratadine (DES) is second-generation antihistamine utilized for managing allergies by blocking histamine action in the body. It also has reported anti-inflammatory and antioxidant actions.

OBJECTIVE:

DES was investigated for its repurposing potential in UC by preclinical screening in TNBS-induced colitis in Wistar rats.

METHODS:

Therapeutic efficacy of DES was evaluated both individually and in combination with standard drug 5-aminosalicylicacid (5-ASA). Rats were orally administered DES (10 mg/kg), 5-ASA (25 mg/kg), and DES + 5-ASA (5 mg + 12.15 mg) following the induction of colitis. Parameters including disease activity score rate (DASR), colon/body weight ratio (CBWR), colon length, diameter, pH, histological injury, and scoring were evaluated. Inflammatory biomarkers such as IL-1ß, TNF-α, along with reduced glutathione (GSH), and malondialdehyde (MDA) were assessed.

RESULTS:

Significant protective effects of DES, especially in combination with 5-ASA, against TNBS-induced inflammation were observed as evidenced by reduced DASR, CBWR, and improved colon morphology. Drugs significantly lowered plasma and colon histamine and, cytokines levels. GSH restoration, and decreased MDA content were also observed.

CONCLUSION:

DES and DES + 5-ASA demonstrated potential in alleviating colonic inflammation associated with TNBS-induced colitis in rats. The effect can be attributed to its antihistamine, anticytokine, and antioxidative properties.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Trinitrobenzenossulfônico / Ratos Wistar / Loratadina / Colite / Anti-Inflamatórios / Antioxidantes Limite: Animals Idioma: En Revista: Immunopharmacol Immunotoxicol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Trinitrobenzenossulfônico / Ratos Wistar / Loratadina / Colite / Anti-Inflamatórios / Antioxidantes Limite: Animals Idioma: En Revista: Immunopharmacol Immunotoxicol Ano de publicação: 2024 Tipo de documento: Article